-
1
-
-
2342466734
-
Global prevalence of diabetes: estimates for the year 2000 and projections for 2030
-
Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
-
(2004)
Diabetes Care
, vol.27
, pp. 1047-1053
-
-
Wild, S.1
Roglic, G.2
Green, A.3
-
2
-
-
80051986265
-
Globalization of Diabetes: the role of diet, lifestyle, and genes
-
Hu FB. Globalization of Diabetes: the role of diet, lifestyle, and genes. Diabetes Care 2011; 34: 1249-1257.
-
(2011)
Diabetes Care
, vol.34
, pp. 1249-1257
-
-
Hu, F.B.1
-
3
-
-
66149131064
-
Diabetes in Asia: epidemiology, risk factors, and pathophysiology
-
Chan JC, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009; 301: 2129-2140.
-
(2009)
JAMA
, vol.301
, pp. 2129-2140
-
-
Chan, J.C.1
Malik, V.2
Jia, W.3
-
4
-
-
0035990614
-
Asians are different from Caucasians and from each other in their body mass index/body fat per cent relationship
-
Deurenberg P, Deurenberg-Yap M, Guricci S. Asians are different from Caucasians and from each other in their body mass index/body fat per cent relationship. Obes Rev 2002; 3: 141-146.
-
(2002)
Obes Rev
, vol.3
, pp. 141-146
-
-
Deurenberg, P.1
Deurenberg-Yap, M.2
Guricci, S.3
-
5
-
-
0042879891
-
Age, body mass index and Type 2 diabetes-associations modified by ethnicity
-
Nakagami T, Qiao Q, Carstensen B, et al. Age, body mass index and Type 2 diabetes-associations modified by ethnicity. Diabetologia 2003; 46: 1063-1070.
-
(2003)
Diabetologia
, vol.46
, pp. 1063-1070
-
-
Nakagami, T.1
Qiao, Q.2
Carstensen, B.3
-
6
-
-
1942423595
-
The associations of body mass index, C-peptide and metabolic status in Chinese Type 2 diabetic patients
-
Chan WB, Tong PC, Chow CC, et al. The associations of body mass index, C-peptide and metabolic status in Chinese Type 2 diabetic patients. Diabet Med 2004; 21: 349-353.
-
(2004)
Diabet Med
, vol.21
, pp. 349-353
-
-
Chan, W.B.1
Tong, P.C.2
Chow, C.C.3
-
7
-
-
3042672692
-
Insulin secretion and insulin sensitivity at different stages of glucose tolerance: a cross-sectional study of Japanese type 2 diabetes
-
Fukushima M, Usami M, Ikeda M, et al. Insulin secretion and insulin sensitivity at different stages of glucose tolerance: a cross-sectional study of Japanese type 2 diabetes. Metabolism 2004; 53: 831-835.
-
(2004)
Metabolism
, vol.53
, pp. 831-835
-
-
Fukushima, M.1
Usami, M.2
Ikeda, M.3
-
8
-
-
0037212264
-
Impaired beta-cell function and insulin sensitivity in Japanese subjects with normal glucose tolerance
-
Kuroe A, Fukushima M, Usami M, et al. Impaired beta-cell function and insulin sensitivity in Japanese subjects with normal glucose tolerance. Diabetes Res Clin Pract 2003; 59: 71-77.
-
(2003)
Diabetes Res Clin Pract
, vol.59
, pp. 71-77
-
-
Kuroe, A.1
Fukushima, M.2
Usami, M.3
-
9
-
-
57349160286
-
Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes
-
Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009; 52: 17-30.
-
(2009)
Diabetologia
, vol.52
, pp. 17-30
-
-
Nathan, D.M.1
Buse, J.B.2
Davidson, M.B.3
-
10
-
-
29944436303
-
-
International Diabetes Federation. International Diabetes Federation, Available at (accessed 6 July 2011).
-
International Diabetes Federation. Global Guideline for Type 2 Diabetes. International Diabetes Federation, 2005. Available at http://www.idf.org/webdata/docs/IDF%20GGT2D.pdf (accessed 6 July 2011).
-
(2005)
Global Guideline for Type 2 Diabetes
-
-
-
11
-
-
33745250519
-
The status of diabetes control and antidiabetic drug therapy in Japan-a cross-sectional survey of 17,000 patients with diabetes mellitus (JDDM 1)
-
Kobayashi M, Yamazaki K, Hirao K, et al. The status of diabetes control and antidiabetic drug therapy in Japan-a cross-sectional survey of 17, 000 patients with diabetes mellitus (JDDM 1). Diabetes Res Clin Pract 2006; 73: 198-204.
-
(2006)
Diabetes Res Clin Pract
, vol.73
, pp. 198-204
-
-
Kobayashi, M.1
Yamazaki, K.2
Hirao, K.3
-
12
-
-
77954731903
-
Present status of sulfonylurea treatment for type 2 diabetes in Japan: second report of a cross-sectional survey of 15,652 patients
-
Arai K, Matoba K, Hirao K, et al. Present status of sulfonylurea treatment for type 2 diabetes in Japan: second report of a cross-sectional survey of 15, 652 patients. Endocr J 2010; 57: 499-507.
-
(2010)
Endocr J
, vol.57
, pp. 499-507
-
-
Arai, K.1
Matoba, K.2
Hirao, K.3
-
13
-
-
0032511566
-
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
-
UK Prospective Diabetes Study (UKPDS) Group.
-
UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
-
(1998)
Lancet
, vol.352
, pp. 854-865
-
-
-
14
-
-
0032511583
-
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
-
UK Prospective Diabetes Study (UKPDS) Group
-
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
-
(1998)
Lancet
, vol.352
, pp. 837-853
-
-
-
15
-
-
0031964322
-
UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes
-
UK Prospective Diabetes Study Group.
-
UK Prospective Diabetes Study Group. UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. Diabetes Care 1998; 21: 87-92.
-
(1998)
Diabetes Care
, vol.21
, pp. 87-92
-
-
-
16
-
-
84873199812
-
-
(exenatide) [abbreviated prescribing information]. Eli Lilly and Company Limited, Basingstoke, Available at (accessed 3 August 2011).
-
Bydureon (exenatide) [abbreviated prescribing information]. Eli Lilly and Company Limited, Basingstoke, 2011. Available at http://www.bydureonlaunch.co.uk/templates/lilly/bydureon/ downloads/prescribing-information.pdf (accessed 3 August 2011).
-
(2011)
Bydureon
-
-
-
17
-
-
15444367142
-
Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus
-
Kolterman OG, Kim DD, Shen L, et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005; 62: 173-181.
-
(2005)
Am J Health Syst Pharm
, vol.62
, pp. 173-181
-
-
Kolterman, O.G.1
Kim, D.D.2
Shen, L.3
-
18
-
-
0347360186
-
Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes
-
Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 2004; 117: 77-88.
-
(2004)
Regul Pept
, vol.117
, pp. 77-88
-
-
Nielsen, L.L.1
Young, A.A.2
Parkes, D.G.3
-
19
-
-
57949096314
-
Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea
-
Gao Y, Yoon KH, Chuang LM, et al. Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea. Diabetes Res Clin Pract 2009; 83: 69-76.
-
(2009)
Diabetes Res Clin Pract
, vol.83
, pp. 69-76
-
-
Gao, Y.1
Yoon, K.H.2
Chuang, L.M.3
-
20
-
-
79961065111
-
Improved glycemic control and reduced bodyweight with exenatide: a double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks
-
Kadowaki T, Namba M, Imaoka T, et al. Improved glycemic control and reduced bodyweight with exenatide: a double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks. J Diabetes Invest 2011; 2: 210-217.
-
(2011)
J Diabetes Invest
, vol.2
, pp. 210-217
-
-
Kadowaki, T.1
Namba, M.2
Imaoka, T.3
-
21
-
-
67650490677
-
Exenatide exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes
-
Kadowaki T, Namba M, Yamamura A, et al. Exenatide exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes. Endocr J 2009; 56: 415-424.
-
(2009)
Endocr J
, vol.56
, pp. 415-424
-
-
Kadowaki, T.1
Namba, M.2
Yamamura, A.3
-
22
-
-
17144371646
-
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea
-
Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28: 1083-1091.
-
(2005)
Diabetes Care
, vol.28
, pp. 1083-1091
-
-
Kendall, D.M.1
Riddle, M.C.2
Rosenstock, J.3
-
23
-
-
0037045845
-
Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study
-
Zander M, Madsbad S, Madsen JL, et al. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002; 359: 824-830.
-
(2002)
Lancet
, vol.359
, pp. 824-830
-
-
Zander, M.1
Madsbad, S.2
Madsen, J.L.3
-
24
-
-
34247259577
-
The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial
-
Zinman B, Hoogwerf BJ, Duran GarciaS, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2007; 146: 477-485.
-
(2007)
Ann Intern Med
, vol.146
, pp. 477-485
-
-
Zinman, B.1
Hoogwerf, B.J.2
Duran, G.3
-
25
-
-
18144401971
-
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes
-
DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28: 1092-1100.
-
(2005)
Diabetes Care
, vol.28
, pp. 1092-1100
-
-
DeFronzo, R.A.1
Ratner, R.E.2
Han, J.3
-
26
-
-
34249891874
-
Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes
-
Kim D, MacConell L, Zhuang D, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007; 30: 1487-1493.
-
(2007)
Diabetes Care
, vol.30
, pp. 1487-1493
-
-
Kim, D.1
MacConell, L.2
Zhuang, D.3
-
27
-
-
79955960213
-
DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide
-
Wysham C, Bergenstal R, Malloy J, et al. DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. Diabet Med 2011; 28: 705-714.
-
(2011)
Diabet Med
, vol.28
, pp. 705-714
-
-
Wysham, C.1
Bergenstal, R.2
Malloy, J.3
-
28
-
-
73549096393
-
Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes
-
Iwamoto K, Nasu R, Yamamura A, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes. Endocr J 2009; 56: 951-962.
-
(2009)
Endocr J
, vol.56
, pp. 951-962
-
-
Iwamoto, K.1
Nasu, R.2
Yamamura, A.3
-
29
-
-
53249142132
-
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
-
Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008; 372: 1240-1250.
-
(2008)
Lancet
, vol.372
, pp. 1240-1250
-
-
Drucker, D.J.1
Buse, J.B.2
Taylor, K.3
-
30
-
-
56549107405
-
Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes
-
Linnebjerg H, Park S, Kothare PA, et al. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul Pept 2008; 151: 123-129.
-
(2008)
Regul Pept
, vol.151
, pp. 123-129
-
-
Linnebjerg, H.1
Park, S.2
Kothare, P.A.3
-
31
-
-
79955661908
-
DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes
-
Blevins T, Pullman J, Malloy J, et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 2011; 96: 1301-1310.
-
(2011)
J Clin Endocrinol Metab
, vol.96
, pp. 1301-1310
-
-
Blevins, T.1
Pullman, J.2
Malloy, J.3
-
32
-
-
77953859640
-
Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial
-
Diamant M, Van GaalL, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010; 375: 2234-2243.
-
(2010)
Lancet
, vol.375
, pp. 2234-2243
-
-
Diamant, M.1
Van, G.2
Stranks, S.3
-
33
-
-
14744287394
-
Glycemic management of type 2 diabetes: an emerging strategy with oral agents, insulins, and combinations
-
Riddle MC. Glycemic management of type 2 diabetes: an emerging strategy with oral agents, insulins, and combinations. Endocrinol Metab Clin North Am 2005; 34: 77-98.
-
(2005)
Endocrinol Metab Clin North Am
, vol.34
, pp. 77-98
-
-
Riddle, M.C.1
-
34
-
-
7444228521
-
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes
-
Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2628-2635.
-
(2004)
Diabetes Care
, vol.27
, pp. 2628-2635
-
-
Buse, J.B.1
Henry, R.R.2
Han, J.3
-
35
-
-
4644300651
-
Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes
-
Fineman MS, Shen LZ, Taylor K, et al. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabetes Metab Res Rev 2004; 20: 411-417.
-
(2004)
Diabetes Metab Res Rev
, vol.20
, pp. 411-417
-
-
Fineman, M.S.1
Shen, L.Z.2
Taylor, K.3
-
36
-
-
0343247711
-
Biodegradation and biocompatibility of PLA and PLGA microspheres
-
Anderson J, Shive M. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 1997; 28: 5-24.
-
(1997)
Adv Drug Deliv Rev
, vol.28
, pp. 5-24
-
-
Anderson, J.1
Shive, M.2
-
37
-
-
84860250733
-
Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment
-
Fineman MS, Mace MF, Diamant M, et al. Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment. Diabetes Obes Metab 2012; 14: 546-554.
-
(2012)
Diabetes Obes Metab
, vol.14
, pp. 546-554
-
-
Fineman, M.S.1
Mace, M.F.2
Diamant, M.3
|